Covered recipient · General Payments record
ROBERT A HOZMAN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$16,013.85
491 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $7,435.49 | 484 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,750.00 | 4 |
| Honoraria | $1,800.00 | 1 |
| Education | $28.36 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 6 of 10; records 251–300 of 491 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT A HOZMAN
NPI 1659308237 · CMS profile ID 119677
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
SKOKIE, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 10; records 251–300 of 491 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1659308237?year=2021&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT A HOZMAN, NPI 1659308237, CMS profile ID 119677. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 10; records 251–300 of 491 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659308237?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ROBERT A HOZMAN, NPI 1659308237, CMS profile ID 119677. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 10; records 251–300 of 491 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659308237?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ROBERT A HOZMAN, NPI 1659308237, CMS profile ID 119677, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 10; records 251–300 of 491 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659308237?year=2021&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
491 matching records · $16,013.85 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 491.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $2,025.00 | 06/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826419129 | CMS |
| Horizon Therapeutics plc | $0.39 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797150459 | CMS |
| Horizon Therapeutics plc | $23.12 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797150461 | CMS |
| AbbVie Inc. | $23.50 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873939 | CMS |
| Mallinckrodt Hospital Products Inc. | $19.83 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845360423 | CMS |
| Mallinckrodt Hospital Products Inc. | $0.74 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845360425 | CMS |
| AbbVie Inc. | $17.26 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873935 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.15 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829273597 | CMS |
| AstraZeneca Pharmaceuticals LP | $34.82 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830241577 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.05 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783504641 | CMS |
| Novo Nordisk Inc | $18.91 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811726840 | CMS |
| Horizon Therapeutics plc | $17.35 | 06/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797150457 | CMS |
| AbbVie Inc. | $8.75 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873927 | CMS |
| AbbVie Inc. | $6.57 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873932 | CMS |
| Radius Health, Inc. | $17.85 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830714569 | CMS |
| PFIZER INC. | $18.42 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832565415 | CMS |
| GlaxoSmithKline, LLC. | $900.00 | 06/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803068709 | CMS |
| Novartis Pharmaceuticals Corporation | $1.36 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723289 | CMS |
| UCB, Inc. | $24.95 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807307265 | CMS |
| UCB, Inc. | $0.36 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807357525 | CMS |
| Amgen Inc. | $15.15 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825727619 | CMS |
| Janssen Biotech, Inc. | $18.26 | 06/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788527303 | CMS |
| Biohaven Pharmaceuticals, Inc. | $14.38 | 06/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852520735 | CMS |
| AbbVie Inc. | $11.67 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873923 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.83 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763461024 | CMS |
| Novartis Pharmaceuticals Corporation | $4.95 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723279 | CMS |
| Novartis Pharmaceuticals Corporation | $14.60 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723281 | CMS |
| Novartis Pharmaceuticals Corporation | $1.28 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723287 | CMS |
| AbbVie Inc. | $20.75 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873919 | CMS |
| Mallinckrodt Hospital Products Inc. | $17.89 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845360421 | CMS |
| Amgen Inc. | $24.52 | 05/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825727727 | CMS |
| Mallinckrodt Hospital Products Inc. | $6.64 | 05/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845360419 | CMS |
| UCB, Inc. | $14.17 | 05/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807356933 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.54 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763461026 | CMS |
| Novartis Pharmaceuticals Corporation | $18.94 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723277 | CMS |
| Novartis Pharmaceuticals Corporation | $1.06 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723285 | CMS |
| Amgen Inc. | $18.89 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825727587 | CMS |
| Lilly USA, LLC | $26.64 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818740267 | CMS |
| AbbVie Inc. | $22.09 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873915 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.96 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829390281 | CMS |
| UCB, Inc. | $18.11 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807344267 | CMS |
| Novartis Pharmaceuticals Corporation | $4.48 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723275 | CMS |
| Novartis Pharmaceuticals Corporation | $2.07 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812723283 | CMS |
| Amgen Inc. | $13.83 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825727563 | CMS |
| Biohaven Pharmaceuticals, Inc. | $12.49 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852520733 | CMS |
| Mallinckrodt Hospital Products Inc. | $19.32 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845360417 | CMS |
| AbbVie Inc. | $21.28 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794873911 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.24 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763461028 | CMS |
| Janssen Biotech, Inc. | $3.33 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788527299 | CMS |
| Janssen Biotech, Inc. | $16.66 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788527301 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $413,374.35 | 63 |
| PY2024 | Principal investigator | $328,896.36 | 85 |
| PY2023 | Principal investigator | $369,966.04 | 80 |
| PY2022 | Principal investigator | $426,739.18 | 141 |
| PY2021 | Principal investigator | $470,828.07 | 117 |
| PY2020 | Principal investigator | $609,642.45 | 95 |
| PY2019 | Principal investigator | $409,370.05 | 74 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
63 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $7,070.00 | 12/22/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400162 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,675.73 | 12/17/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223289888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,800.00 | 12/15/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175400231 |
| Principal investigator 1 | ABBVIE INC. | $3,604.60 | 12/04/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202528120 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,144.19 | 12/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223289120 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,070.00 | 11/27/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400258 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $469.94 | 11/10/2025 | Non-covered Recipient Entity HOZMAN, ROBERT A, OFFICE | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL | No dispute reported | 06/30/2026 | 1190309310 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,017.25 | 11/07/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223288155 |
| Principal investigator 1 | ABBVIE INC. | $8,372.60 | 11/04/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202520091 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,700.00 | 11/03/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175400238 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,705.00 | 10/27/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400220 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,675.73 | 10/15/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286997 |
| Principal investigator 1 | ABBVIE INC. | $1,295.50 | 10/09/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202515867 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,500.00 | 10/06/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175400165 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,000.00 | 10/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286057 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,833.70 | 10/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,405.00 | 09/29/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400264 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $29.07 | 09/24/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431040 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $926.96 | 09/04/2025 | Non-covered Recipient Entity Clinical Investigation Specialists, Inc | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) | No dispute reported | 06/30/2026 | 1235998062 |
| Principal investigator 1 | ABBVIE INC. | $3,567.80 | 09/03/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202507395 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,544.75 | 09/03/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223284917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,335.00 | 08/28/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400177 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,650.00 | 08/28/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175400182 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 08/22/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223284537 |
| Principal investigator 1 | Eli Lilly and Company | $3,500.00 | 08/20/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187879165 |
| Principal investigator 1 | ABBVIE INC. | $13,500.00 | 08/06/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202502336 |
| Principal investigator 1 | ABBVIE INC. | $2,327.50 | 08/05/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202501152 |
| Principal investigator 1 | ABBVIE INC. | $2,141.90 | 08/05/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202501154 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,500.00 | 08/04/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175400188 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,544.75 | 08/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223283423 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,370.00 | 08/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223283525 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 08/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223283527 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $937.00 | 08/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223283529 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,535.00 | 07/28/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400207 |
| Principal investigator 1 | ABBVIE INC. | $8,500.00 | 07/25/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis | No dispute reported | 06/30/2026 | 1202499768 |
| Principal investigator 1 | ABBVIE INC. | $349.00 | 07/02/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202496137 |
| Principal investigator 1 | ABBVIE INC. | $2,750.00 | 07/02/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202496139 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,485.00 | 06/30/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400194 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $10,500.00 | 06/11/2025 | Non-covered Recipient Entity Clinical Investigation Specialists, Inc | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235998060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,725.00 | 06/09/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400170 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,000.00 | 06/04/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223280682 |
| Principal investigator 1 | UCB SA | $54,209.00 | 06/04/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS, INC | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246658608 |
| Principal investigator 1 | ABBVIE INC. | $5,997.90 | 06/03/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202488911 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 05/15/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS | A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis | No dispute reported | 06/30/2026 | 1202484961 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $174.42 | 05/07/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431038 |
| Principal investigator 1 | ABBVIE INC. | $3,943.00 | 05/06/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202481187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,605.00 | 05/01/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400271 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,650.87 | 04/23/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431032 |
| Principal investigator 1 | Vertex Pharmaceuticals Incorporated | $8,841.15 | 04/09/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1214124052 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,440.60 | 04/08/2025 | Non-covered Recipient Entity HOZMAN, ROBERT A, OFFICE | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL | No dispute reported | 06/30/2026 | 1190302301 |
| Principal investigator 1 | ABBVIE INC. | $2,243.75 | 04/03/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202471852 |
| Principal investigator 1 | ABBVIE INC. | $5,443.00 | 04/03/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202471856 |
| Principal investigator 1 | ABBVIE INC. | $9,127.50 | 03/07/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202460907 |
| Principal investigator 1 | ABBVIE INC. | $3,239.30 | 03/06/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202457863 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $967.14 | 03/03/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431028 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,900.00 | 02/20/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175400245 |
| Principal investigator 1 | UCB SA | $1,279.00 | 02/18/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS, INC | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246657692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,500.00 | 02/17/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400226 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 02/17/2025 | Non-covered Recipient Entity CLINICAL INVESTIGATION SPECIALISTS INC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175400253 |
| Principal investigator 1 | ABBVIE INC. | $3,234.20 | 02/05/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202445498 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $43,223.55 | 01/21/2025 | Non-covered Recipient Entity Robert Hozman Health | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235994191 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $87.00 | 01/15/2025 | Non-covered Recipient Entity HOZMAN, ROBERT A, OFFICE | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190302299 |
| Principal investigator 1 | ABBVIE INC. | $2,210.00 | 01/02/2025 | Non-covered Recipient Entity CLIN INVESTIGATION SPECIALISTS INC | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202435509 |